urine test for
prostate / bladder cancer
diagnosis

What We Do

NuView Diagnostics has developed a proprietary genomic urine screening test, NDX-VPAC1™, in which pilot data has shown to be highly accurate in binding to shed cancer cells confirming the presence of disease in men prior to undergoing a surgical biopsy. Potentially a screening test as well, over 1 million unneeded biopsies could be prevented saving over $3B a year. Other cancer cells identified in urine studies to date also include shed bladder cells a first of kind test for the early detection of bladder cancer.
"We need a better screen, obsession with PSA has delayed research progress"

Urine_640x400-01

Collect Sample

Lab scientist working with medical samples and centrifuge

Centrifuge Sample

VPAC_Bloom-01

Cancer Blooms Under Microscope

Publication on Urine Assay Targeting VPAC1

Objective
To validate a hypothesis that prostate cancer can be detected
non-invasively by a simple and reliable assay by targeting
genomic VPAC receptors expressed on malignant prostate
cancer cells shed in voided urine.

Want to Learn More?

We welcome inquiries with interested individuals, media and potential investors. Please drop us a note in the contact form or call us directly.

Contact Address

NuView Diagnostics LLC
1389 Center Drive, Suite 250
Park City, UT 84098

Contact Details

TEL 888.902.7779
FAX 435.647.5602

Office Hours

9:00am to 5:00pm
Monday to Friday

Your Name (required)

Your Email (required)

Your Phone

Subject

Your Message